The objective of this study is to determine the minimum dose of ACAM2000 needed to produce a cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age and previously vaccinated against smallpox.

Condition	Treatment or Intervention	Phase
Smallpox	Vaccine: Smallpox	Phase II

Further Study Details: 

Expected Total Enrollment:  350

Specifically, the objectives of this study are to: 1. Compare the safety and tolerability of four dose levels of ACAM2000 and a standard dose of Dryvax® in healthy adults at least 28 years of age and previously vaccinated to smallpox. Safety and tolerability will be determined by examination of the local cutaneous reaction, adverse events, physical examinations, vital signs, structured interviews, and laboratory analysis. 2. Determine the immunogenicity of four dose levels of ACAM2000 and a standard dose of Dryvax® in healthy adults at least 28 years of age by comparing: a. the proportion of subjects at each dose level who develop a major cutaneous reaction b. the proportion of subjects in each treatment group who develop neutralizing antibodies, including the fold-increase in antibody titer between Baseline and Day 30 sera; and the geometric mean vaccinia neutralizing antibody titer on Day 30. 3. Determine the minimum dose of ACAM2000 that is calculated to produce a major cutaneous reaction in at least 90% of a population of healthy adults at least 28 years of age, with a history of smallpox vaccination.

Ages Eligible for Study:  28 Years and above,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

INCLUSION:

• have a history of previous smallpox vaccination greater than 10 years previous to the date of screening and presence of a vaccination scar.
• females must not be pregnant, lactating and must agree to use an effective form of birth control for the 30 days following vaccination or unable to bear children.
• agree to be available for the entire study and agree to comply with all requirements.

EXCLUSION:

• children 1 year of age or younger in the household or be in close contact
• smallpox vaccination within ten years
• known or suspected HIV infection, primary immunodeficiency disorder, leukemia, lymphoma, or current radiation treatment or use of immunosuppressive or anti-neoplastic drugs or have a household member or intimate contact with the conditions listed above.
• renal disease
• current or past history of eczema or a household member or direct contact who has eczema.
• known allergy or past allergic reactions to latex gloves or to antibiotics which include neomycin, streptomycin, chlortetracycline, and polymyxin B
• known allergy or past allergic reaction to blood products.
• known allergy to cidofovir or sulfa-containing drugs.
• history of allergic phenomena following smallpox vaccination in the past, including urticaria, erythema multiforme, or Stevens-Johnson syndrome.
• transfusion of blood or treatment with any blood product.
• current or history of drug or alcohol abuse
• innoculation with any other live vaccine or participating in another drug or vaccine trial within 30 days of enrollment.

Kansas
      PRA International, Lenexa,  Kansas,  66219,  United States
Missouri
      Bio-Kinetic Clinical Applications, Springfield,  Missouri,  65802,  United States
Rhode Island
      Memorial Hospital of Rhode Island Division of Infectious Diseases, Pawtucket,  Rhode Island,  02860,  United States

Study ID Numbers:  H-400-003
Record last reviewed:  April 2004
Last Updated:  October 13, 2004
Record first received:  January 30, 2003
ClinicalTrials.gov Identifier:  NCT00053482
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08